Bank of New York Mellon Corp Sells 58,881 Shares of Amedisys, Inc. (NASDAQ:AMED)

Bank of New York Mellon Corp trimmed its stake in Amedisys, Inc. (NASDAQ:AMED) by 19.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 239,989 shares of the health services provider’s stock after selling 58,881 shares during the period. Bank of New York Mellon Corp owned about 0.73% of Amedisys worth $22,230,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Raymond James Financial Inc. acquired a new position in shares of Amedisys during the fourth quarter worth $215,000. Swiss National Bank boosted its stake in shares of Amedisys by 0.9% during the 4th quarter. Swiss National Bank now owns 64,400 shares of the health services provider’s stock worth $5,847,000 after acquiring an additional 600 shares in the last quarter. Xponance Inc. boosted its stake in shares of Amedisys by 3.5% during the 4th quarter. Xponance Inc. now owns 4,349 shares of the health services provider’s stock worth $395,000 after acquiring an additional 148 shares in the last quarter. Magnetar Financial LLC lifted its stake in Amedisys by 0.3% in the 4th quarter. Magnetar Financial LLC now owns 637,443 shares of the health services provider’s stock valued at $57,873,000 after buying an additional 1,835 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Amedisys in the 4th quarter valued at about $590,000. 94.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AMED has been the topic of a number of research reports. Wall Street Zen lowered shares of Amedisys from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 24th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Amedisys currently has an average rating of “Hold” and an average price target of $100.75.

Amedisys Price Performance

Amedisys stock opened at $97.47 on Friday. The stock has a market cap of $3.20 billion, a P/E ratio of 35.97, a price-to-earnings-growth ratio of 1.32 and a beta of 0.94. The company has a fifty day simple moving average of $95.97 and a 200-day simple moving average of $93.69. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.27.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.12. Amedisys had a net margin of 3.79% and a return on equity of 12.52%. The company had revenue of $594.78 million for the quarter, compared to analyst estimates of $597.43 million. During the same period in the previous year, the business posted $1.03 earnings per share. Amedisys’s quarterly revenue was up 4.1% on a year-over-year basis. Equities analysts expect that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.